Does Glecaprevir And Pibrentasvir Interact with Efavirenz?
CDI records a major classification for Glecaprevir And Pibrentasvir and Efavirenz. The stored summary is: May significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect. Coadministration is not recommended. The mechanism involves induces p-gp and cyp3a. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Glecaprevir And Pibrentasvir Class
- Hepatitis C Virus NS5A Inhibitor
- Efavirenz Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Induces P-gp and CYP3A
What To Tell Your Doctor or Pharmacist
If you are taking Glecaprevir And Pibrentasvir and your doctor is considering prescribing Efavirenz (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider